Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp

But Frontline NSCLC Was Biggest Opportunity

Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.

Merck KGaA Darmstadt
Merck KGaA, Darmstadt: the company is counting on its oncology pipeline to boost revenues to €2bn by 2022. • Source: Getty Images

Merck KGaA and GlaxoSmithKline have seen their ambition to expand in oncology badly dented by the failure of a key Phase III lung cancer trial.

Bintrafusp alfa is one of the most important assets for both companies, but the INTR@PID Lung 037 trial in non-small...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip